. 2024 Aug 27;6(5):684–696. doi: 10.1016/j.jaccao.2024.07.010

Table 3.

Logistic Regression Results for Primary and Secondary Outcomes

	Indicator	Group	Total	Adjusted OR (95% CI)^a	P Value
Primary^a
	cTnT	Enalapril	42/54 (77.7)	0.65 (0.23-1.78)^b	0.41^c
		Standard care	45/54 (83.3)
Secondary^a
	cTnI	Enalapril	25/53 (47.2)	1.10 (0.50-2.38)	0.82^c
		Standard care	24/53 (45.2)
	GLS	Enalapril	10/47 (21.2)	0.95 (0.33-2.74)	0.92^c
	GLS	Standard care	9/41 (21.9)	0.95 (0.33-2.74)	0.92^c
	LVEF	Enalapril	2/49 (4.1)	N/A	0.24^d
	LVEF	Standard care	0/48 (0.0)	N/A	0.24^d
	Any cardiotoxicity per BSE/BCOS^e	Enalapril	10/47 (21.2)	0.95 (0.33-2.74)	0.92^c
	Any cardiotoxicity per BSE/BCOS^e	Standard care	9/41 (21.9)	0.95 (0.33-2.74)	0.92^c
	Asymptomatic CTRCD cardiotoxicity per ESC^f	Enalapril	42/49 (85.7)	0.55 (0.13-2.01)	0.37^c
	Asymptomatic CTRCD cardiotoxicity per ESC^f	Standard care	44/48 (91.6)	0.55 (0.13-2.01)	0.37^c

Values are n/n (%), unless otherwise indicated.

BSE/BCOS = British Society of Echocardiography/British Cardio-Oncology Society; cTnI = cardiac troponin I; cTnT = cardiac troponin T; CTRCD = cancer therapy–related cardiac dysfunction; ESC = European Society of Cardiology; GLS = global longitudinal strain; LVEF = left ventricular ejection fraction; RD = risk difference; RR = risk ratio.

Intention-to-treat analyses for all outcomes, adjusted for chemotherapy regimen.

RD: −0.06 (95% CI: −0.20 to 0.08); RR: 0.89 (95% CI: 0.76-1.05).

P value obtained from logistic regression.

Obtained from Firth’s logistic regression.

Includes all possible, probable, and definite cases of cardiotoxicity in accordance with the BSE/BCOS guidelines.

Includes mild, moderate, and severe CTRCD calculated using cTnT.